Alzheimer's Disease Neuroimaging Initiative 4
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- University of Southern California
- Study ID
- NCT05617014
- Status
- Enrolling By Invitation
Conditions
- Alzheimer Disease
- Dementia
- Mild Cognitive Impairment
Eligibility Criteria
- Sex
- ALL
- Age
- 55 Years - 90 Years
- Healthy Volunteers
- Accepted
Interventions
- Neuraceq — RADIATIONAmyloid PET imaging with Florbetaben (Neuraceq) injection
- Amyvid — RADIATIONAmyloid PET imaging with Amyvid (Florbetapir) injection
- Tauvid — RADIATIONTau PET imaging with Tauvid (Flortaucipir) injection
- MK-6240 — RADIATIONTau PET imaging with MK-6240 injection
- NAV4694 — RADIATIONAmyloid PET imaging with NAV4694 injection
- PI-2620 — RADIATIONTau PET imaging with PI-2620 injection
Study Details
The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline. ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.
Key Dates
- Start date
- Jun 9, 2023
- Status verified
- May 2026
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
Study Design
- Enrollment
- 1,500 participants (estimated)
Arms
- Arm: Cognitively Normal (CN)700 participants with no apparent memory problems, which is anticipated to include 250 newly enrolled participants and 450 rollover participants from the prior ADNI3 study without apparent memory problems.
- Arm: Mild Cognitive Impairment (MCI)450 participants with mild cognitive impairment (MCI), which is anticipated to include 250 newly enrolled participants and 200 rollover participants from the prior ADNI3 study with MCI.
- Arm: Dementia (DEM)350 participants with mild dementia (DEM), which is anticipated to include 250 newly enrolled participants and 100 participants followed from the prior ADNI3 study with dementia.
Primary Outcome Measure
Rate of enrollment of Underrepresented Populations (URPs) [ Time Frame: 5 years ]
Locations (59)
Find similar trials in Birmingham, AL
Related Studies
- Alzheimer's Disease Genetics StudyRecruiting · Indiana University · Nationwide, Indiana
- Wisconsin Brain Donor ProgramEnrolling By Invitation · University of Wisconsin, Madison · Madison, Wisconsin
- DaTSCAN Imaging in Aging and Neurodegenerative DiseasePHASE4 · Enrolling By Invitation · Mayo Clinic · Rochester, Minnesota
- Genetic Characterization of Movement Disorders and DementiasRecruiting · National Institute on Aging (NIA) · Baltimore, Maryland